At BCAL Diagnostics, we believe early and accurate detection is key to improving breast cancer outcomes. As an Australian and US-based biotechnology company, we are pioneering a non-invasive blood test designed to complement existing breast screening methods and provide women with greater confidence in their results.
1 in 7 Women in Australia Will Be Diagnosed with Breast Cancer in their lifetime*
Our Mission
For over a decade, BCAL Diagnostics has been committed to developing innovative, accessible technologies that enhance breast cancer screening.
Our goal is to empower women and their clinicians with diagnostic tools that improve early detection and streamline the screening process.
Designed to Complement Mammography
Our first-in-class blood test is designed to work alongside mammography, providing an added layer of screening for women with dense breast tissue. Complementing traditional imaging, the test helps rule out breast cancer, improving diagnostic accuracy and bring greater confidence to patients and healthcare providers.
BCAL Diagnostics is led by a team of experts with deep experience in biotechnology, diagnostics, and healthcare innovation. Our leadership is dedicated to advancing scientific excellence and bringing practical, life-changing solutions to women worldwide.
Dedicated to Advancing Early Detection
BCAL Diagnostics is committed to transforming breast cancer screening with innovative, non-invasive diagnostic technology. Our mission is to empower women and clinicians worldwide with early, accurate detection, improving health outcomes and confidence in screening results.
Jayne Shaw Co-Founder and Executive Chair, Dr John Hurrell Non-Executive Director and Consultant, Shane Ryan Chief Executive Officer
What we do
BCAL Diagnostics is advancing non-invasive breast cancer screening with a simple blood test designed to complement existing imaging technologies.
Initially developed to support mammograms, our solutions aim to evolve into a comprehensive screening and monitoring approach for women worldwide. By integrating seamlessly with other screening methods, we empower healthcare professionals to improve patient outcomes with greater confidence.
For over a decade, BCAL Diagnostics has been developing a non-invasive diagnostic tool designed to enhance breast cancer screening – resulting in a simple blood test that complements mammography to rule out breast cancer in women over 30 with high breast density .
An effective and accurate blood test should increase the screening detection rate and reduce mortality. A lipidomic signature from plasma used to detect localized breast cancer would be clinically valuable.
Source: * Breast Cancer Statistics, Breast Cancer Trials est. 2024 figures https://www.breastcancertrials.org.au/breast-cancer-resources/breast-cancer-statistics
